PIN2 RETROSPECTIVE ANALYSIS OF IMIPENEM/CILASTIN VERSUS PIPRACILLIN/TAZOBACTAM IN TREATMENT OF INFECTED NEUTROPENIC PATIENTS  by Egan, TF & McGhan, WF
256 Abstracts
prescribed NSAIDs were ibuprofen (47%), naproxen
(22%) and etodolac (14%). The calculated risk level 
indicated that 29% of patients had substantial (4%) or
signiﬁcant (25%) risk for a potential GI event, of 
which 34% were prescribed criteria-based therapy 
(salsalate, non-selective NSAID plus proton pump
inhibitor (PPI), high-dose famotidine or misoprostol, or
COX-2 inhibitor).
CONCLUSIONS: In this study, salsalate, non-selective
NSAIDs with PPI, high-dose famotidine or misoprostol,
and COX-2 inhibitor are under utilized in patients at high
risk for a GI event.
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Previous investigation revealed that plan members diag-
nosed with conditions that usually have a viral etiology
receive antibiotics at high rates. Multiple reasons exist for
this inappropriate drug use. One possible reason may 
be that providers, patients, or both believe that using 
an antibiotic will prevent the onset a more serious con-
dition and thereby prevent a return visit. Identiﬁcation of
the causes of antibiotic use will help design interven-
tions to control the development of antibiotic-resistant
microorganisms.
OBJECTIVE: Determine the impact of antibiotic use on
return visits for acute respiratory tract infections.
METHODS: This study uses large database analysis
(insurance claims data). Inclusion criteria: age less than
65 and continuous enrollment in a non-HMO beneﬁt
plan with medical, hospital, and pharmaceutical cover-
age. Cases were identiﬁed as an outpatient service for a
common cold, upper respiratory tract infection, or acute
bronchitis. Antibiotic use was deﬁned as a prescription
ﬁlled within seven days of the respiratory tract infection.
Patients were followed for an additional 30 days to deter-
mine whether they had a subsequent service for a respi-
ratory tract infection or related condition.
RESULTS: There were 173,469 patients who met study
criteria, overall 101,446 received antibiotics (58.48%).
For those who received an antibiotic, 14,600 (14.39%)
returned for a respiratory tract infection within 30 days
of their initial diagnosis. Of those not receiving an 
antibiotic at their ﬁrst visit (72,023), 12.27% returned 
for a subsequent respiratory tract infection within 30 days
of their initial diagnosis. Although the difference between
the groups is statistically signiﬁcant (p < 0.0001), the
magnitude is not clinically signiﬁcant.
CONCLUSION: The use of antibiotics for acute respira-
tory tract infections does not affect the rate of return for
subsequent visits within 30 days. Communicating this
information to providers and patients could help reduce
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Serious infections in neutropenic patients may have mor-
tality rates in excess 40%, even when properly treated.
OBJECTIVE: This retrospective database analysis was
performed to examine the mortality, length of stay and
cost of imipenem/cilastin versus piperacillin/tazobactam
in the treatment of seriously infected neutropenic
patients.
METHODS: The data were collected from July 1997 to
June 1998 at 90 non-government non-specialty acute care
hospitals over 100 beds throughout the United States. The
data collected at discharge included UB-92, diagnostics,
procedures, ICD-9’s, DRG and drug dispensing data. All
patients in the analysis were coded for a serious infection,
primarily pneumonia (481 to 486.99) or septicemia (038
to 038.9), and neutropenia (284,284.4, 284.9 and 288).
RESULTS: The database analysis identiﬁed 16,396 on
mipenem/cilastin or piperacillin/tazobactam over 18 years
of age. Of those treated with these agents, 2,563 were
infected neutropenia patients. The length of stay was 
not statistically signiﬁcant between the two groups. 
Difference in utilization patterns demonstrates the
imipenem/cilastin group had a statistically signiﬁcant (p
< 0.05) greater use as a third line (16%) agent and less
as a ﬁrst line agent (61%) than the piperacillin/tazobac-
tam group (10% and 68% respectively). Mortality rates
indicated imipenem/cilastin had statistically signiﬁcant
lower mortality rate (17.1%) versus the piperacillin/
tazobactam (20.6%) group in the treatment groups.
Overall cost was $1,130 lower in the imipenem/cilastin
treated group despite the fact the drug cost was $267
higher. 
CONCLUSION: In this study population, imipenem/
cilastin has a lower mortality rate, a higher drug cost and
lower overall treatment cost in infected neutropenic
patients when compared to piperacillin/tazobactam.
